Front Row Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Front Row Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40	Closed	-$149	–	511
2024 Q3	$149	Hold	40	–	–	﹤0.01%	486
2024 Q2	$224	Hold	40	–	–	﹤0.01%	919
2024 Q1	$210	Hold	40	–	–	﹤0.01%	906
2023 Q4	$209	Hold	40	–	–	﹤0.01%	455
2023 Q3	$631	Hold	40	–	–	﹤0.01%	880
2023 Q2	$1K	Hold	40	–	–	﹤0.01%	877
2023 Q1	$1K	Buy	+40	New	+$1.19K	﹤0.01%	897
2022 Q4	–	Sell	-40	Closed	-$1K	–	954
2022 Q3	$1K	Hold	40	–	–	﹤0.01%	911
2022 Q2	$2K	Hold	40	–	–	﹤0.01%	856
2022 Q1	$2K	Hold	40	–	–	﹤0.01%	884
2021 Q4	$2K	Hold	40	–	–	﹤0.01%	898
2021 Q3	$2K	Hold	40	–	–	﹤0.01%	892
2021 Q2	$2K	Hold	40	–	–	﹤0.01%	895
2021 Q1	$2K	Hold	40	–	–	﹤0.01%	891
2020 Q4	$2K	Hold	40	–	–	﹤0.01%	853
2020 Q3	$2K	Hold	40	–	–	﹤0.01%	851
2020 Q2	$2K	Hold	40	–	–	﹤0.01%	889
2020 Q1	$2K	Hold	40	–	–	﹤0.01%	863
2019 Q4	$2K	Hold	40	–	–	﹤0.01%	822
2019 Q3	$2K	Hold	40	–	–	﹤0.01%	827
2019 Q2	$2K	Hold	40	–	–	﹤0.01%	886
2019 Q1	$2K	Buy	+40	New	+$1.78K	﹤0.01%	883

Other funds holding EGRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

SLG

Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Front Row Advisors's EGRX Position: Q4 2024 in Review

Front Row Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 40 shares — an estimated $149 sold.

Front Row Advisors first reported a position in EGRX in Q1 2019 and held it in 22 quarters. The position peaked at $2K in Q2 2022. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

Front Row Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
Front Row Advisors sold 40 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $149.
Front Row Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2019 and held it in 22 quarters.
Front Row Advisors's Eagle Pharmaceuticals, Inc. position peaked at $2K in Q2 2022.
9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Front Row Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.